Shanghai Bio-heart Biological Technology (HKG:2185) obtained approval for Iberis Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System from China's National Medical Products Administration for the treatment of hypertension patients, a Wednesday filing with the Hong Kong bourse said.
The system has been developed by unit Shanghai AngioCare Medical Technology, according to the interventional cardiovascular device company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.